The effect of hormonal secretion on survival in adrenocortical carcinoma: A multi-center study
Nenhuma Miniatura disponível
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2024
Título da Revista
ISSN da Revista
Título do Volume
Editora
MOSBY-ELSEVIER
Autores
SADA, Alaa
FOSTER, Trenton R.
AL-WARD, Ruaa
SAWANI, Sahar
PISHDAD, Reza
BEN-SHLOMO, Anat
DY, Benzon M.
LYDEN, Melanie L.
BERGSLAND, Emily
Citação
SURGERY, v.175, n.1, p.80-89, 2024
Resumo
Background: Current evidence suggests that cortisol secreting adrenocortical carcinoma has worse prognosis compared to non-secreting adrenocortical carcinoma. However, the effect of other secretory subtypes is unknown.Methods: This multicenter study within the American-Australian-Asian Adrenal Alliance included adults with adrenocortical carcinoma (1997-2020). We compared overall survival and disease-free survival among cortisol secreting, mixed cortisol/androgen secreting, androgen secreting, and non-secreting adrenocortical carcinoma.Results: Of the 807 patients (mean age 50), 719 included in the secretory subtype analysis: 24.5% were cortisol secreting, 13% androgen secreting, 28% mixed cortisol/androgen, 32.5% non-secreting, and 2% were mineralocorticoid secreting. Median overall survival and disease-free survival for the entire cohort were 60 and 9 months, respectively.Median overall survival was 36 months for cortisol, 30 for mixed, 60 for androgen secreting, and 115 for non-secreting adrenocortical carcinoma, P < .01. Median disease-free survival was 7 months for cortisol, 8 for mixed, 10 for androgen, and 12 for non-secreting adrenocortical carcinoma, P 1/4 .06. On multivariable analysis of age, sex, Ki67%, secretory subtype, stage, resection, and adjuvant therapy, predictors of worse overall survival were older age, higher Ki67%, stage IV, mixed secreting, R1, and no adjuvant therapy, P < .05. On subgroup analysis of R0 resection, predictors of worse overall survival included older age and higher Ki67%. Ki67% >= 40, stage III and cortisol secretion were associated with worse disease-free survival.Conclusion: Mixed cortisol/androgen secreting adrenocortical carcinoma was associated with worse overall survival, while cortisol or androgen secreting alone were not. Notably, among patients after R0 resection, secretory subtype did not affect overall survival. Cortisol secreting adrenocortical carcinoma demonstrated worse disease-free survival. Ki67% remained a strong predictor of worse overall survival and disease-free survival independent of stage.(c) 2023 Elsevier Inc. All rights reserved.
Palavras-chave
Referências
- Abiven G, 2006, J CLIN ENDOCR METAB, V91, P2650, DOI 10.1210/jc.2005-2730
- Ayala-Ramirez M, 2013, EUR J ENDOCRINOL, V169, P891, DOI 10.1530/EJE-13-0519
- Berruti A, 2014, EUR UROL, V65, P832, DOI 10.1016/j.eururo.2013.11.006
- Beuschlein F, 2015, J CLIN ENDOCR METAB, V100, P841, DOI 10.1210/jc.2014-3182
- Daher M, 2022, J CLIN ENDOCR METAB, V107, P1239, DOI 10.1210/clinem/dgac046
- Else T, 2014, ENDOCR REV, V35, P282, DOI 10.1210/er.2013-1029
- Erdogan I, 2013, J CLIN ENDOCR METAB, V98, P181, DOI 10.1210/jc.2012-2559
- Glenn JA, 2019, SURGERY, V165, P186, DOI 10.1016/j.surg.2018.04.068
- Kebebew E, 2006, WORLD J SURG, V30, P872, DOI 10.1007/s00268-005-0329-x
- Nieman LK, 2008, J CLIN ENDOCR METAB, V93, P1526, DOI 10.1210/jc.2008-0125
- Puglisi S, 2018, ENDOCRIN METAB CLIN, V47, P395, DOI 10.1016/j.ecl.2018.02.003
- Sada A, 2021, WORLD J SURG, V45, P188, DOI 10.1007/s00268-020-05801-x
- Sada A, 2020, SURGERY, V167, P216, DOI 10.1016/j.surg.2019.04.066
- Sharma Eliza, 2018, J Clin Med Res, V10, P636, DOI 10.14740/jocmr3503w
- Srougi V, 2022, J CLIN ENDOCR METAB, V107, P964, DOI 10.1210/clinem/dgab865
- Vanbrabant T, 2018, EUR J ENDOCRINOL, V179, P429, DOI 10.1530/EJE-18-0450
- Zeiger MA, 2009, ENDOCR PRACT, V15, P450, DOI 10.4158/EP.15.5.450